Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Salvi, Samanta ^a   Gurioli, Giorgia ^a   Martignano, Filippo ^a   Foca, Flavia ^a   Gunelli, Roberta ^b   Cicchetti, Giacomo ^c   De Giorgi, Ugo ^a   Zoli, Wainer ^a   Calistri, Daniele ^a   Casadio, Valentina ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c BUFALINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BLADDER DISEASE; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA INTEGRITY; DNA ISOLATION; DNA SEQUENCE; DNA STRUCTURE; EARLY DIAGNOSIS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUPERNATANT; URINALYSIS; CASE CONTROL STUDY; CHEMISTRY; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; URINE;

AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DNA; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN;

EID: 84941039754     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/574120     Document Type: Article

References (26)

1. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013, " CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
2. S. A. Strope and G. L. Andriole, "Prostate cancer screening: current status and future perspectives, " Nature Reviews Urology, vol. 7, no. 9, pp. 487-493, 2010.
3. A. R. Alberts, I. G. Schoots, and M. J. Roobol, "Prostate-specific antigen-based prostate cancer screening: past and future, " International Journal ofUrology, vol. 22, no. 6, pp. 524-532, 2015.
4. F. Labrie, "PSA screening for prostate cancer: why so much controversy?" Asian Journal of Andrology, vol. 15, no. 5, pp. 603-607, 2013.
5. O. W. Brawley, D. P. Ankerst, and I.M. Thompson, "Screening for prostate cancer, " CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 264-273, 2009.
6. E. A. M. Heijnsdijk, A. der Kinderen, E. M. Wever, G. Draisma, M. J. Roobol, and H. J. De Koning, "Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer, " British Journal of Cancer, vol. 101, no. 11, pp. 1833-1838, 2009.
7. S. Loeb, M. G. Sanda, D. L. Broyles et al., "The prostate health index selectively identifies clinically significant prostate cancer, " The Journal of Urology, vol. 193, no. 4, pp. 1163-1169, 2015.
8. J. K. Birnbaum, Z. Feng, R. Gulati et al., "Projecting benefits and harms of novel cancer screening biomarkers: a Study of PCA3 and prostate cancer, " Cancer Epidemiology Biomarkers & Prevention, vol. 24, no. 4, pp. 677-682, 2015.
9. R. Wang, A. M. Chinnaiyan, R. L. Dunn, K. J. Wojno, and J. T. Wei, "Rational approach to implementation of prostate cancer antigen 3 into clinical care, " Cancer, vol. 115, no. 17, pp. 3879-3886, 2009.
10. M. Auprich, A. Bjartell, F. K.-H. Chun et al., "Contemporary role of prostate cancer antigen 3 in the management of prostate cancer, " European Urology, vol. 60, no. 5, pp. 1045-1054, 2011.
11. M. J. Roobol, F. H. Schroder, G. L. J. H. van Leenders et al., "Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (100), " European Urology, vol. 58, no. 6, pp. 893-899, 2010.
12. M. Truong, B. Yang, and D. F. Jarrard, "Toward the detection of prostate cancer in urine: a critical analysis, " Journal of Urology, vol. 189, no. 2, pp. 422-429, 2013.
13. T. Todenhofer, J. Hennenlotter, M. Esser et al., "Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer, " Disease Markers, vol. 2014, Article ID 973406, 7 pages, 2014.
14. H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, "Cell-free nucleic acids as biomarkers in cancer patients, " Nature Reviews Cancer, vol. 11, no. 6, pp. 426-437, 2011.
15. V. Casadio, D. Calistri, M. Tebaldi et al., "Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data, " Urologic Oncology, vol. 31, no. 8, pp. 1744-1750, 2013.
16. V. Casadio, D. Calistri, S. Salvi et al., "Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study, " BioMed Research International, vol. 2013, Article ID 270457, 5 pages, 2013.
17. M. Zancan, F. Galdi, F. Di Tonno et al., "Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis, " The International Journal of Biological Markers, vol. 24, no. 3, pp. 147-155, 2009.
18. T. Szarvas, I. Kovalszky, K. Bedi et al., "Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment, " Oncology Reports, vol. 18, no. 2, pp. 405-409, 2007.
19. S. Jahr, H. Hentze, S. Englisch et al., "DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells, " Cancer Research, vol. 61, no. 4, pp. 1659-1665, 2001.
20. P. O. Delgado, B. C. A. Alves, F. De Sousa Gehrke et al., "Characterization of cell-free circulating DNA in plasma in patients with prostate cancer, " Tumor Biology, vol. 34, no. 2, pp. 983-986, 2013.
21. S. Salvi, V. Casadio, V. Conteduca et al., "Circulating cellfree AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone, " British Journal of Cancer, vol. 112, no. 10, pp. 1717-1724, 2015.
22. A. S. Ishkanian, C. A. Mallof, J. Ho et al., "High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer, " Prostate, vol. 69, no. 10, pp. 1091-1100, 2009.
23. J. D. Oxley, M. H. Winkler, D. A. Gillatt, and D. S. Peat, "Her-2/neu oncogene amplification in clinically localised prostate cancer, " Journal of Clinical Pathology, vol. 55, no. 2, pp. 118-120, 2002.
24. G. Johnson, A. A. B. Nour, T. Nolan, J. Huggett, and S. Bustin, "Minimum information necessary for quantitative real-time PCR experiments, " Methods in Molecular Biology, vol. 1160, pp. 5-17, 2014.
25. Y.-H. Su, M. Wang, D. E. Brenner et al., "Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer, " The Journal of Molecular Diagnostics, vol. 6, no. 2, pp. 101-107, 2004.
26. M. L. Blute, N. A. Damaschke, and D. F. Jarrard, "The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications, " Current Opinion in Urology, vol. 25, no. 1, pp. 83-88, 2015.